Abstract:The recent FDA approval of VOQUEZNATM TRIPLE PAKTM 7-day therapy, which includes vonoprazan (VON), amoxicillin (AMO), and clarithromycin (CLA), marks a significant advancement in the treatment of Helicobacter pylori ( H. pylori ) infections. Accurate quantification of these active pharmaceutical ingredients (APIs) is critical for ensuring therapeutic efficacy and safety. However, conventional analytical methods often require extensive sample pretreatment and separation, which can be time-consuming and environmentally burdensome. This study presents the first simultaneous quantification of VON, AMO, and CLA using innovative chemometric-assisted spectrophotometric methods aligned with Green Analytical Chemistry (GAC) principles. Our methods eliminate the need for pretreatment or separation, thereby enhancing both analytical efficiency and environmental sustainability. We developed orthogonal partial least squares (OPLS), principal component regression (PCR), and Artificial Neural Network (ANN) models, utilizing the Design of Experiment (DoE) approach to minimize solvent use and waste.Model validation was achieved through Orthogonal Array-based Latin Hypercube Sampling (OALHS), ensuring robust performance evaluation. The models demonstrated high precision, with recovery percentages ranging from 98.00% to 102.00%. The calibration set model fitting was assessed using the determination coefficient (R 2 ), and the cross-validation coefficient (Q 2 ), all model's R 2 and Q 2 values were close to 1.0, indicating the calibration samples' high capacity for explanation and prediction, while the root mean square error of calibration (RMSEC) values were found to be less than 0.1. The prediction of the validation set was employed by the root mean square error of prediction (RMSEP) and relative root mean square errors of prediction (RRMSEP), the values were found (0.0335–0.0613) and (0.7207–0.5287) for RMSEP and RRMSEP, respectively, while the bias-corrected mean square error of prediction (BCMSEP) was found to be between 0.0014 and 0.0001. To evaluate and enhance the sustainability of the methods, comprehensive tools were utilized: SPIDER Solvent Tool, RGB12 Algorithm, AGREE, and the Need Quality Sustainability (NQS) Index. This work supports the Sustainable Development Goals (SDGs) by demonstrating advancements in environmentally sustainable analytical methods.

DoE Guided Development of an HPLC Method for Evaluation of Amoxicillin and Metronidazole Co-loaded Mucoadhesive GRDDS Formulation for H. pylori Eradication

DoE-Aided Optimization of RP-HPLC Method for Simultaneous Estimation of Amoxicillin and Tinidazole Loaded Mucoadhesive GRDDS Formulation for the Treatment of H. pylori

Development, Optimization and Evaluation of Mucoadhesive Microspheres of Amoxicillin for the Treatment of H.Pylori by Full Factorial Design

An eco-friendly liquid chromatographic analysis of the triple therapy protocol of amoxicillin, metronidazole and vonoprazan for H. Pylori eradication: application to combined dosage forms and simulated gastric fluid

Development and Evaluation of Novel Amoxicillin and Phytic Acid-Loaded Gastro-Retentive Mucoadhesive Pectin Microparticles for the Management of Helicobacter pylori Infections

Development of Gastroretentive Floating Combination Tablets Containing Amoxicillin Trihydrate 500 mg and Levofloxacin 125 mg for Eradicating Resistant Helicobacter pylori

DEVELOPMENT OF GASTRORETENTIVE MUCOADHESIVE SOLID DOSAGES FORM CONTAINING AMOXICILLIN TRIHYDRATE AND RANITIDINE HCL FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTIONS

Preparation and Evaluation of Amoxicillin Loaded Dual Molecularly Imprinted Nanoparticles for Anti-Helicobacter Pylori Therapy.

Validated chromatographic approach for determination of two ternary mixtures in newly approved formulations for helicobacter pylori eradication: assessment of greenness profile and content uniformity

A Novel Gastroretentive Porous Microparticle for Anti-Helicobacter Pylori Therapy: Preparation, in Vitro and in Vivo Evaluation

Design of Enzyme Decorated Mucopermeating Nanocarriers for Eradication of H. Pylori Infection

Chemometric-assisted spectrophotometric methods for simultaneous drug determination in new Helicobacter pylori treatment regimens - Environmental sustainability assessment

Stability-indicating HPLC method optimization using quality by design with design of experiments approach for quantitative estimation of organic related impurities of Doripenem in pharmaceutical formulations

AQbD-enhanced green RP-UPLC-PDA methodology for quantification and forced degradation studies for omeprazole, amoxicillin, and rifabutin

Advanced Interpenetrating Polymer Networks for Innovative Gastroretentive Formulations Targeting Helicobacter pylori Gastric Colonization

Researching the Dose Ratio in a Controlled Release Multiple-Drug Delivery System: Using Combination Therapy with Porous Microparticles for the Treatment of Helicobacter Pylori Infection

Mucoadhesive Microspheres: A Promising Delivery System for Helicobacter Pylori (H. pylori) Treatment

Design of Mucoadhesive Nanostructured Polyelectrolyte Complexes Based on Chitosan and Hypromellose Phthalate for Metronidazole Delivery Intended to the Treatment of Helicobacter pylori Infections

Treatment of H. pylori infection and gastric ulcer: Need for novel Pharmaceutical formulation

Implementation of DMAIC principle-based analytical quality by design approach to simultaneous estimation of metronidazole and ofloxacin by HPTLC method

Development of a Berberine Loaded Multifunctional Design for the Treatment of Helicobacter pylori Induced Gastric Ulcer